Understanding Human Growth Hormone Therapy for Children

What is Human Growth Hormone?

Human growth hormone (hGH) is a protein produced naturally by the pituitary gland, a small gland located at the base of the brain. During childhood and adolescence, hGH plays a central role in stimulating bone growth, muscle development, and the regulation of body composition. It signals the liver and other tissues to produce insulin-like growth factor 1 (IGF-1), which mediates many of growth hormone's effects on the body's tissues and organs.

When the pituitary gland does not produce sufficient hGH, children may grow more slowly than their peers and may not reach a typical adult height without physician-supervised intervention.

Recombinant human growth hormone (somatropin) is a synthetic version of the naturally occurring hormone, produced using recombinant DNA technology. It is structurally identical to the hGH produced by the human body. Somatropin received FDA approval in 1985, and its safety profile has been established over more than 40 years of clinical use and post-marketing surveillance.

FDA-Approved Uses in Children

Recombinant hGH (somatropin) has received FDA approval for several specific pediatric indications. A physician must evaluate and diagnose the underlying condition before considering whether therapy may be appropriate for any individual child. Approved pediatric indications currently include:

Additional FDA-approved pediatric indications include:

• Prader-Willi Syndrome — a genetic disorder associated with short stature, low muscle tone, and growth hormone deficiency
• Small for Gestational Age (SGA) — children born smaller than expected for gestational age who have not caught up in growth by age 2–4
• Chronic Kidney Disease (CKD) — children with renal insufficiency who experience growth failure

The appropriateness of therapy for any specific child is determined solely by the treating physician based on a thorough clinical evaluation. Discuss your child's specific situation with a qualified physician.

How is HGH Administered?

When physician-supervised hGH therapy is determined to be appropriate, it is typically administered as a daily subcutaneous (under the skin) injection. Key points about administration include:

• Injections are generally given once daily, typically in the evening to align with the body's natural overnight growth hormone release patterns
• The needle used is small, similar in size to those used for insulin pens, and most families report that children adapt quickly with practice
• Injections are self-administered at home by a parent or caregiver, following thorough training provided by the supervising physician's team
• Dosage is determined entirely by the treating physician and is based on factors including the child's weight, specific diagnosis, and individual response to therapy as monitored over time
• Injection sites are rotated to minimize discomfort and skin reactions

The physician's office will provide detailed instruction and ongoing support to families throughout the treatment period.

Safety Profile

Clinical studies spanning decades have established a well-documented safety profile for physician-supervised recombinant hGH therapy in eligible pediatric patients. As with any medical treatment, it is important for families to have a thorough discussion of potential benefits and risks with the treating physician before any decisions are made.

Commonly Reported Side Effects

Some patients experience side effects that are generally mild and manageable, including:

• Injection site reactions such as redness, swelling, or mild discomfort at the injection site
• Temporary headache, particularly when therapy is first initiated
• Mild fluid retention in some patients

Less Common and Serious Side Effects

Serious side effects are rare but can occur. These should be discussed thoroughly with the treating physician and may include changes in blood glucose regulation, rare cases of elevated intracranial pressure, and other systemic effects. Ongoing physician monitoring is a standard component of care during any treatment period.

What the Evaluation Process Looks Like

Before any treatment consideration, a physician will conduct a thorough medical evaluation to determine whether a growth concern has an identifiable cause and whether any intervention may be appropriate. Our Growth Evaluation page provides a detailed overview of this process. Common components of a pediatric growth evaluation may include:

• Growth hormone stimulation testing — a blood test performed after stimulating the pituitary gland to assess the child's ability to produce hGH
• Bone age assessment — an X-ray of the wrist that allows the physician to estimate skeletal maturity and remaining growth potential
• IGF-1 and IGFBP-3 lab work — blood markers that reflect overall growth hormone activity
• Comprehensive growth history review — analysis of the child's height measurements over time plotted against standard growth charts
• Physical examination — conducted by the physician to assess overall health and development
• Additional labs and imaging as determined appropriate by the physician

These diagnostic findings collectively inform the physician's clinical assessment and any treatment considerations. HGHKids.com facilitates connection with physicians who perform these evaluations in Irvine, California.

Important Considerations for Families

• Ongoing monitoring is required. Physician-supervised hGH therapy involves regular follow-up appointments, lab work, and growth measurements throughout the treatment period to assess response and make dosage adjustments.
• Not appropriate for all children. HGH therapy is only considered when specific diagnostic criteria are met. It is not appropriate for children who are simply shorter than average without a qualifying medical indication.
• Open growth plates are required. Once a child's growth plates (epiphyseal plates) have fused — which typically occurs by the mid-to-late teenage years — height-increasing effects of hGH therapy are no longer possible. Timing of evaluation matters, and families are encouraged to seek evaluation while their child's growth plates remain open.
• Insurance coverage varies. Insurance coverage for hGH therapy depends on the specific diagnosis, the insurer, and the policy. Coverage is more commonly available for confirmed growth hormone deficiency than for other indications. Discuss insurance and financial considerations directly with the physician's office.
• Commitment is required. Daily injections and regular physician visits represent a meaningful commitment for families. Understanding this before beginning therapy is important.